IceCure Medical (NASDAQ:ICCM) Stock Rating Raised to “Hold” at Zacks Research

IceCure Medical (NASDAQ:ICCM) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday, Zacks reports.

A number of other research firms have also recently issued reports on ICCM. Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a research report on Friday, July 17th. Wall Street Zen lowered shares of IceCure Medical from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $30.00.

IceCure Medical Stock Up 1.9%

Shares of NASDAQ ICCM opened at $1.10 on Monday. IceCure Medical has a 52 week low of $1.03 and a 52 week high of $26.97. The firm’s fifty day moving average is $2.15 and its 200 day moving average is $4.86.

IceCure Medical (NASDAQ:ICCM) last posted its quarterly earnings results on Tuesday, June 30th. The company reported ($1.60) EPS for the quarter. The firm had revenue of $0.91 million for the quarter. IceCure Medical had a negative net margin of 427.67% and a negative return on equity of 174.26%. Equities research analysts expect that IceCure Medical will post -4.61 EPS for the current fiscal year.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is an Israel-based medical technology company that develops minimally invasive cryoablation systems for the treatment of tumors. Its technology uses liquid nitrogen to freeze and destroy targeted tissue, with the goal of providing an alternative to surgical removal in selected patients.

The company’s primary product is the ProSense system, which is designed to deliver controlled cryoablation through a probe inserted into a tumor. IceCure has focused on applications in breast, kidney, lung, and other solid tumors, including procedures performed under image guidance.